modelAgomelatine
Extends from Pharmacolibrary.Drugs.ATC.N.N06AX22.
Information
| name: | Agomelatine | |
| ATC code: | N06AX22 | route: | oral |
| compartments: | 1 | |
| dosage: | 25 | mg |
| volume of distribution: | 35 | L |
| clearance: | 1100 | mL/min |
| other parameters in model implementation | ||
Agomelatine is an antidepressant that acts as an agonist at melatonergic MT1 and MT2 receptors and as an antagonist at 5-HT2C serotonin receptors. It is used primarily in the treatment of major depressive disorder in adults. Agomelatine is approved in several countries for clinical use in depression.
Pharmacokinetics
Pharmacokinetic parameters summarized for healthy adult subjects after oral administration as single and multiple doses.
References
Xie, F, et al., & Cheng, Z (2019). A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers. British journal of clinical pharmacology 85(5) 1003–1014. DOI:10.1111/bcp.13902 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30761579
Song, L, et al., & Wang, L (2014). Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers. Journal of clinical pharmacy and therapeutics 39(2) 204–209. DOI:10.1111/jcpt.12118 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24372004
ElKady, EF, et al., & Farouk, F (2018). Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 1102-1103 135–142. DOI:10.1016/j.jchromb.2018.10.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30388703
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)